Norethisterone - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

estalis continuous 50/250 estradiol 50mcg/day norethisterone acetate 250mcg/day patch sachet

sandoz pty ltd - norethisterone acetate, quantity: 4.8 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 250 microgram); estradiol, quantity: 0.512 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polyethylene terephthalate; ethylene/vinyl acetate copolymer; polyvinylidene flouride; ethyl acetate; ethanol; toluene; acrylates/va copolymer; polytrimethylhydrosilylsiloxane; xylene; ammonia; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

estalis continuous 50/140 estradiol 50mcg/day norethisterone acetate 140mcg/day patch sachet

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 140 microgram); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.